Image courtesy of VuComp
January 29, 2015 — VuComp Inc. announced that two additional patents have been issued to the company, extending its intellectual property related to computer-aided detection of breast cancer.
The patents cover a key cancer detection component of the M-Vu CAD system. Together, they include the ability to find suspicious looking calcification clusters and areas with spiculations, which make the system sensitive to finding areas of interest that are consistent with cancer. VuComp has another seven patents pending related to its breast cancer detection products.
VuComp’s M-Vu CAD system was the first mammography CAD product to meet the FDA standard that recommends comprehensive reader studies to prove the effectiveness of CAD systems.
"The new patents continue to distinguish VuComp as a pioneer in the development of the most advanced CAD system for mammography," said James Pike, president and chief technology officer, VuComp. "Our commitment to advancing our technology and adding to our intellectual property estate delivers tremendous value to our customers, patients and investors."
For more information: www.vucomp.com
April 20, 2026 
